Status: Recruiting
CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors.
This is a prospective, single-arm, single-center, open-label clinical study, aiming to evaluate the efficacy and safety of CAR-T combined with ASCT in the treatment of relapsed/refractory large B-cell lymphoma with high-risk factors.
Participants needed: 20
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Zhejiang Cancer HospitalUpdated: May 13, 2026Locations: 1
Eligibility criteria
Age ≥ 18 years [+9]
Patients who have previously received any CD19-targeted therapy [+5]